NEVRO CORP. (NYSE:NVRO) Files An 8-K Results of Operations and Financial ConditionItem 2.02
Results of Operations and Financial Condition.
NEVRO CORP. (NYSE:NVRO) Files An 8-K Results of Operations and Financial Condition
On July 5, 2017, Nevro Corp. (“Nevro” or the “Company”) issued a press release relating to its preliminary unaudited revenue for the three months ended June 30, 2017. The full text of the press release is furnished herewith as Exhibit 99.1.
The information in this Item 2.02 of this Current Report on Form 8-K and the related Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Effective as of July 3, 2017, Michael Enxing, Vice President of Sales, is no longer with the Company.
|
Item 2.02 |
Financial Statements and Exhibits. |
|
ExhibitNo. |
Description |
|
99.1 |
Press release dated July 5, 2017. |
NEVRO CORP ExhibitEX-99.1 2 nvro-ex991_45.htm EX-99.1 nvro-ex991_45.htm Exhibit 99.1 Nevro Announces Preliminary Unaudited Second Quarter 2017 Revenue and Business Update Company Reiterates Revenue Guidance for Full Year 2017 REDWOOD CITY,…To view the full exhibit click here
About NEVRO CORP. (NYSE:NVRO)
Nevro Corp. is a medical device company. The Company has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy offers back pain relief in addition to leg pain relief. HF10 therapy also provides pain relief without paresthesia. HF10 therapy offers benefits to patients, physicians and hospitals. The Company’s Senza is designed to create electrical impulses from 2 hertz to 10 kilohertz (kHz), including its HF10 therapy. HF10 therapy delivers waveforms at 10 kHz pulse rate with a statistically driven and clinically verified programming algorithm. Senza consists of leads, a trial stimulator, an implantable pulse generator (IPG), surgical tools, a clinician laptop programmer, a patient remote control and a mobile charger. NEVRO CORP. (NYSE:NVRO) Recent Trading Information
NEVRO CORP. (NYSE:NVRO) closed its last trading session down -0.49 at 73.94 with 230,739 shares trading hands.
